reimbursement
Orphan Drugs – Reinventing Economies of Scale
November 16 by Cristina FalcãoEconomies of scale come in many flavors. Including the oddity flavor where the number of manufactured products decreases and the size of markets shrink. Orphan drugs are economies of scale’...
The Potential Benefits of HTA Centralisation
February 24 by Pharma IQIt is quickly becoming clear in the pharmaceutical industry that price and value are two defining issues, with organisations constantly striving to develop optimum strategies for understanding value...
Russia: Localisation vs. Isolation - Part Two
February 08 by Cyrus ChowdhuryPharma2020 – Towards Self-Reliance or the WTO? In late 2008, The Russian Federation’s Ministry of Industry and Trade announced the Pharma2020 strategy as part of the Healthcare Develo...
Where is Health Technology Assessment Going?
November 04 by Pharma IQChrissie Fletcher, Director and Head of International Biostatistics at Amgen, talks to Helen Winsor from Pharma IQ, about innovation in clinical design, analysis and reporting. Fletcher disc...
Das Arzneimittelsparpaket: Wie kann sich die Pharmaindustrie auf die neuen Rahmenbedingungen einstellen?
July 28 by Pharma IQIn this Pharma IQ podcast, Isabel Henkel, Director, Access & Reimbursement at Johnson & Johnson Medical, talks about how the pharma industry needs to adjust to the new requirements of the...
Boardroom Series: Interview with Almirall's CSO Bertil Lindmark
April 26 by Bertil LindmarkBertil Lindmark is the current Chief Scientific Officer and Executive Director of R&D at Almirall and member of Almirall’s Management Board. He has been in this position since January 2011 and in...